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646 CHEST ReviewsBiomarkers have the potential to become central to the clinical evaluation and monitoring of
patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Here we summarize the current understanding of putative serum, BAL fluid, and genetic bio-
markers in this setting, according to their hypothesized pathobiologic mechanisms: evidence of
epithelial cell dysfunction (eg, Krebs von den Lungen-6 antigen), fibroblast proliferation and
extracellular matrix production or turnover (eg, matrix metalloproteinase-1), or immune
dysregulation (eg, CC chemokine ligand 18). While most of the available data come from
idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrosing ILD, data are available
in the broader patient population of chronic fibrosing ILDs. A number of these biomarkers show
promise, however, none have been validated. In this review article, we assess both the status of
proposed biomarkers for chronic fibrosing lung diseases with a progressive phenotype in pre-
dicting disease risk or predisposition, diagnosis, prognosis, and treatment response and provide
a direct comparison between IPF and other chronic fibrotic ILDs. We also reflect on the current
clinical usefulness and future direction of research for biomarkers in the setting of chronic
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Over 200 distinct pulmonary disorders are under the
heading of interstitial lung disease (ILD), with idiopathic
pulmonary fibrosis (IPF) being the most recognized.1
Characterized by the development of progressive
pulmonary fibrosis, IPF results in lung function and
quality-of-life deterioration and worsening respiratory
symptoms.2 A similar chronic progressive fibrosing
phenotype occurs in varying proportions of patients
with other fibrotic ILDs—for example, idiopathic
nonspecific interstitial pneumonia (iNSIP),
hypersensitivity pneumonitis (HP), systemic sclerosis
(SSc)-associated ILD (SSc-ILD), rheumatoid arthritis
(RA)-associated ILD (RA-ILD), and sarcoidosis.
Although no formal definition of “progressive” exists,
Cottin et al3 suggest that patients meeting any of the
following criteria within a 24-month period have
experienced disease progression: a relative decline
of $ 10% in FVC, a relative decline of $ 15% in
diffusing capacity of the lungs for carbon monoxide
(DLCO), or worsening symptoms or radiologic
appearance accompanied by a $ 5% relative decrease in
FVC. All patients with ILD with a chronic progressive
fibrosing phenotype share some clinical, radiologic, and
pathologic characteristics.4-8 The prognosis is broadly
consistent across cohorts of individuals with chronic
fibrosing ILDs with a progressive phenotype,
strengthening the rationale for grouping these diseases.
However, determining an individual patient’s risk of
progression, long-term prognosis, and likelihood of
treatment response is challenging because of the
intrinsic variability seen among patients with the same
diagnosis.
A biomarker may be defined as “any substance,
structure, or process that can be measured in the body or
its products and influences or predicts the incidence of
outcome or disease.”9 For the purposes of this article, we
have considered molecular (protein and RNA) markers
that can be quantified in biological tissue or fluids (eg,
whole blood, serum, BAL fluid [BALF], induced
sputum) that reflect physiologic or pathologic processes
or that reflect pharmacologic responses to a therapeutic
intervention.10 Nonprotein biomarkers (eg,
mitochondrial markers, microRNA, quantitative
imaging, cell counts in BALF, lung microbiome analyses,
lung physiology) are beyond the scope of this article.
Biomarker development has been identified as a key step
toward establishing personalized medicine.11 In the field
of chronic fibrosing ILDs with a progressive phenotype,
biomarker development aims to establish easily
measurable variables that allow improved clinicalchestjournal.orgclassification of different ILDs, predict prognosis or
likelihood of response to therapy, or monitor treatment
response.12
This review describes the typical classification of
currently proposed biomarkers according to their
hypothesized pathobiologic mechanisms: alveolar
epithelial cell injury, inflammation and fibrosis, tissue
remodeling and repair, and immunologic changes.10,13
We subsequently examine the most promising serum
and BALF biomarkers and propose to classify them by
whether they are associated with disease predisposition,
diagnosis, disease progression and prognosis, or
response to treatment. We elaborate this classification
further by directly comparing biomarker profiles of IPF
and non-IPF chronic fibrosing ILDs with a progressive
phenotype. Finally, we provide an analysis of the current
clinical usefulness of biomarkers in fibrosing ILDs and
offer recommendations for future biomarker
development and research directions.
Candidate Biomarkers by Mechanistic Pathway
Some of the most promising biomarkers of chronic
fibrosing ILDs with a progressive phenotype are markers
of proposed mechanisms involved in disease
pathogenesis.
Epithelial Cell Dysfunction
A number of molecules are markers of alveolar epithelial
cell injury or regeneration.14 Krebs von den Lungen-6
(KL-6), a submolecule of mucin 1,15 is a glycoprotein
expressed in type II pneumocytes and bronchiolar
epithelial cells that may be involved in promoting the
migration, proliferation, and survival of lung
fibroblasts.16 The mucin gene MUC5B encodes mucin
5B, a major gel-forming protein in human airway
secretions that has been linked to the maintenance of
airway health.17 Surfactant protein A (SP-A) and
surfactant protein D (SP-D) are lipoprotein complexes
secreted by type II pneumocytes and airway cells; they
are involved in stabilizing alveolar surface tension at the
air-liquid interface and supporting lung host innate
immunity.13 Chitinase-3-like protein 1 (YKL-40) is a
chitinase-like protein involved in innate immune system
and cell processes in relation to extracellular matrix
(ECM) remodeling.13
ECM Turnover
The development of pulmonary fibrosis is characterized
by increased turnover of ECM. Transforming growth
factor-b plays an important role but has not been widely647
explored as a pulmonary fibrosis biomarker due to its
ubiquity and the difficulty of accurately quantifying it.
Other markers of ECM production and turnover,
however, appear more promising. Matrix
metalloproteinases (MMPs) are zinc-dependent protease
enzymes regulating ECM remodeling.13,18 Lysyl oxidase-
like 2 (LOXL2) catalyzes the cross-linking of collagen
and has been identified as a key mediator of fibrosis.19 It
is highly expressed in fibrosing lungs and is believed to
play key roles in ECM remodeling and
fibrogenesis.10,13,20 Insulinlike growth factor (IGF) has
been shown to stimulate the production of ECM by
fibroblasts and to encourage epithelial cells to
proliferate. IGF-binding proteins (IGFBPs) contribute to
IGF activity by facilitating transportation and receptor
binding of IGF.21,22 Vascular endothelial growth factor
(VEGF) is a growth factor with proangiogenic activity
and is believed to help protect the epithelium from
injury and to encourage tissue repair.23 In response to
lung injury, airway club cells produce and release a low-
molecular-weight protein, the 16-kDa Clara cell
secretory protein (CC16).13 Periostin is an ECM protein
which belongs to the fasciclin family; serum levels of
periostin increase in IPF and other fibrotic idiopathic
interstitial pneumonias and are associated with declines
in DLCO and vital capacity.24
Immune Dysregulation
These biomarkers include chemokines, cytokines, and
their receptors, of which the most promising are C-C
motif chemokine ligand (CCL) 18 and IL-6.13 CCL18 is
derived from alveolar macrophages and appears to have
numerous functions beyond its role as a
chemoattractant, including the regulation of fibrosis.25
Levels of the proinflammatory and profibrotic cytokineTABLE 1 ] Risk and Predisposition Biomarkers
Disease Mechanistic Path
IPF Epithelial cell dysfunct
ECM remodeling
Immune dysregulation





HLA ¼ human leukocyte antigen; ILD ¼ interstitial lung disease; IPF ¼ idiopath
ILD ¼ systemic sclerosis-associated ILD.
aFor chronic fibrosing ILDs with a progressive phenotype.
648 CHEST ReviewsIL-6 are increased in serum and BALF in many
pulmonary diseases.13Biomarker Applications in Chronic Fibrosing
ILDs With a Progressive Phenotype
Risk and Predisposition Biomarkers
Data in IPF: Some genetic variants have been associated
with an increased likelihood of developing IPF
(Table 1).26-39 Studies suggest that the single nucleotide
polymorphism (SNP) rs35705950 in the promoter
region of the MUC5B gene increases the risk of
developing IPF, although it is associated with a less
progressive form of the disease.26 TOLLIP encodes the
toll-interacting protein, which regulates immune
responses mediated through toll-like receptors,
including the modulation of transforming growth
factor-b signaling.40 Three SNPs in the TOLLIP gene
have been linked with susceptibility to IPF.32 Telomerase
complex genes include TERT and TERC, which encode
telomerase reverse transcriptase and RNA component,
respectively. Heterozygous mutations in either the TERT
or TERC genes, or shortened telomeres, may be
associated with an increased risk of IPF.29 In addition to
these variants in MUC5B, TOLLIP, or TERT and TERC,
a recent resequencing study of 3,624 IPF and 4,442
control samples highlighted that rare variants in the
FAM13A and RTEL1 genes were also contributing to the
genetic risk of developing IPF.31 Human leukocyte
antigen (HLA) class I and II histocompatibility genes
encode HLAs, which regulate the immune response to
presenting antigens. The HLA-A*02-DRB1*04
haplotype has been associated with genetic susceptibility










ion and MUCB5 RA-ILD34
HLA Sarcoidosis,35,36 SSc-ILD,37
RA-ILD38,39
ic pulmonary fibrosis; RA-ILD ¼ rheumatoid arthritis-associated ILD; SSc-
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CC16 ¼ 16-kDa Clara cell secretory protein; CCL ¼ C-C motif chemokine ligand; CRP ¼ C-reactive protein; CTD-ILD ¼ connective tissue disease-associated
ILD; CXCL ¼ C-X-C motif chemokine; HP ¼ hypersensitivity pneumonitis; IGFBP ¼ insulinlike growth factor-binding protein; IIP ¼ idiopathic interstitial
pneumonias; iNSIP ¼ idiopathic nonspecific interstitial pneumonia; KL-6 ¼ Krebs von den Lungen-6; MMP ¼ matrix metalloproteinase; MX1 ¼ myxovirus
resistance protein 1; PAI-1 ¼ plasminogen activator inhibitor-1; RNP ¼ ribonucleoprotein; S100 ¼ S100 calcium-binding protein; SAA ¼ serum amyloid A;
sIL-2R ¼ soluble IL-2 receptor; SP-A ¼ surfactant protein A; SP-D ¼ surfactant protein D; TIMP-1 ¼ tissue inhibitor of metalloproteinase-1; VEGF ¼
vascular endothelial growth factor. See Table 1 legend for expansion of other abbreviations.
aFor chronic fibrosing ILDs with a progressive phenotype.Data in Other Chronic Fibrosing ILDs With a
Progressive Phenotype: As described earlier, there is
evidence that individuals with the SNP rs35705950 in
the MUC5B gene have an increased risk of developing
IPF; this SNP is also associated with an increased risk of
RA-ILD.34 However, rs35705950 does not appear to be
associated with pulmonary fibrosis in SSc, sarcoidosis, or
myositis-associated ILD.41
Certain HLA haplotypes are also associated with the
development of non-IPF ILDs. The HLA-DRB1*1501/
HLA-DQB1*0602 haplotype, for example, has been
associated with chronic sarcoidosis.42 The rare
HLADRB5*01:05 allele may predict the development of
ILD in patients with SSc.37 There is also evidence that
specific HLA alleles, including HLA-DRB1*1502, arechestjournal.orgassociated with an increased risk of ILD in patients with
RA.38,39
Diagnostic Biomarkers
Data in IPF: Elevations in levels of MMP-1 (serum),
MMP-7 (serum, BALF, and induced sputum), and other
MMPs are recognized in IPF (Table 2).13,43-78 In
addition, serum and sputum from patients with IPF
display significantly higher levels of IGFBP-2 (P < .001)
compared with those from healthy subjects.46,47
Increased circulating levels of C-X-C motif chemokine
(CXCL) 13 have been observed in patients with IPF
vs that in healthy control subjects.27 Elevated levels of
the proinflammatory monocyte/macrophage-derived
calcium-binding proteins, S100 calcium-binding protein649
(S100)A8 (also known as calgranulin A—levels
increased in plasma) and S100A9 (calgranulin B—levels
increased in BALF), have been found in IPF.13,51
Although the numbers of circulating fibrocytes
(precursors of fibroblasts) have been suggested to be
increased in patients with IPF,13,79 there are contradictory
data regarding VEGF and its role. Serum levels of VEGF
have been shown to be elevated in patients with IPF,48
whereas BALF levels appear to be reduced in patients with
IPF vs that in healthy control subjects.23,49
Data in Other Chronic Fibrosing ILDs With a
Progressive Phenotype: Elevated KL-6 concentrations
have been reported in the serum and BALF of patients
with idiopathic interstitial pneumonia, HP, pulmonary
sarcoidosis, asbestosis, and connective tissue disease-
associated ILDs (CTD-ILDs).13,38,52-55,80 Recently, BALF
levels of both KL-6 and S100A9 were also found to be
significantly higher in patients with fibrotic iNSIP than
in healthy subjects and were similar to those in patients
with IPF.74 Serum levels of SP-A and/or SP-D are
increased in fibrosing ILDs (eg, HP, iNSIP, SSc-ILD);
high levels of these lipoproteins have been associated
with a progressive phenotype in patients with iNSIP and
with decreases in DLCO and FVC.13,38,56 Increased
concentrations of the chemokine CC16 have also been
observed in the serum and BALF of patients with
pulmonary sarcoidosis, asbestosis, and SSc-ILD.58-60
Increased levels of MMP-1 and MMP-7 have been
reported in sarcoidosis, RA-ILD, and SSc-ILD.61-63 Serum
levels of MMP-7 are significantly higher in patients with
RA-ILD vs those in patients with RA without ILD.64
Increased serum and/or BALF levels of other MMPs and
tissue inhibitors of MMPs (tissue inhibitor of
metalloproteinases) have been reported in various
ILDs.13,38 For example, BALF levels of MMP-2 are higher
in patients with nonspecific interstitial pneumonia than in
those with IPF.65 It was reported that, among patients with
elevated MMP-7, the absence of concurrent increases in
SP-D and osteopontin suggests the presence of a non-IPF
or nonusual interstitial pneumonia pattern ILD.66 Patients
with sarcoidosis have increased expression of MMP-12
vs control subjects, with correlation between expression
levels and disease severity.67 An increased number of
circulating fibrocytes has been observed in patients with
RA-ILDs.81 Just as for IPF, serum levels of S100A8 and
S100A9 were reported to be elevated in SSc, with the
highest levels in patients with lung fibrosis.13,75
A number of chemokines have shown correlations with
the presence of ILD. Elevated levels of CCL18 have been650 CHEST Reviewsfound in the serum, BALF, and lung tissue of patients
with SSc-ILD and other chronic fibrosing ILDs with a
progressive phenotype.68 In sarcoidosis, levels of CCL18
appear to correlate with the extent of disease activity.73
Increased BALF and serum levels of CCL2 were seen in
patients with SSc and have been shown to correlate with
the presence of ILD.69 High levels of CCL15 have been
associated with progressive sarcoidosis.42 CXCL10 and
CXCL11 have also been identified as possible diagnostic
markers for this disease, with the possibility of CXCL10
enabling differentiation between active and inactive
forms.42 Patients with RA with ILD have significantly
higher serum CXCL10 levels than do those without
ILD.64 The cytokine IL-6, known to be elevated in a
variety of inflammatory diseases (such as sepsis),76 was
found to be increased in the BALF of patients with SSc-
ILD, alongside IL-4, IL-7, and IL-8.63,69 Increased levels
of interleukins (eg, IL-12, IL-18) have been associated
with sarcoidosis.42,77 Several other biomarkers related to
immune function—soluble IL-2 receptor (sIL-2R),
C-reactive protein (CRP), and serum amyloid A (serum
amyloid A)—have shown high sensitivity for sarcoidosis.77
Serum autoantibodies and immunologic proteins
associated with pulmonary fibrosis in SSc-ILD include
anti-topoisomerase I antibodies, autoantibodies to small
nuclear ribonucleoproteins (RNPs; eg, anti-U1, -U3 and
-U11/U12 RNPs), and anti-endothelial cell antibodies.38
Serum autoantibodies against myxovirus resistance
protein 1 (MX1) have been identified as a possible
diagnostic biomarker for iNSIP.78 Other potential serum
and BALF biomarkers that have been investigated
include circulating cells and molecules associated with
macrophage or monocyte activation or endothelial cell
injury.13,38,82
Chitotriosidase is an enzyme produced by alveolar
macrophages in patients with sarcoidosis. Detected in
BALF, chitotriosidase levels have been reported to
correlate with the severity of sarcoidosis.42
Prognostic Biomarkers
Data in IPF: Threshold serum levels of KL-6, or
sequential changes in KL-6 levels, have been shown to
predict lung function decline or outcome in patients
with IPF (Table 3).83-131 In addition, increased serum
and BALF YKL-40 levels have been shown to predict
lower survival rates,91 and high levels of circulating
fibrocytes have been associated with increased risk of
mortality.13,79 In patients with IPF, elevated MMP-7 was
strongly associated with reduced survival.44,86,87 High
serum levels of SP-A and/or SP-D have been associated[ 1 5 8 # 2 CHES T A UGU S T 2 0 2 0 ]
TABLE 3 ] Prognostic Biomarkers







































































CA ¼ cancer antigen; CX3CL1 ¼ fractalkine; ICAM-1 ¼ intercellular adhesion molecule 1; IFN-g ¼ interferon gamma; LOXL2 ¼ lysyl oxidase-like 2; VCAM-
1 ¼ vascular cell adhesion molecule 1; YKL-40 ¼ chitinase-3-like protein 1. See Table 1 and 2 legends for expansion of other abbreviations.
aFor chronic fibrosing ILDs with a progressive phenotype.with decreases in DLCO and FVC86,88,89; elevated serum
levels may be useful predictors of survival.86,90
The potential for markers of ECM turnover to serve as
biomarkers was investigated in the Prospective
Observation of Fibrosis in the Lung Clinical Endpoints
(PROFILE) study.132 Six collagen-derived neoepitopes
showed increased serum levels in patients with IPF
compared with those in healthy volunteers and higher
levels in patients with progressive vs stable disease.
Patients with IPF showing faster rates of increase in
these biomarkers over 3 months showed more rapid
disease progression and reduced survival. Serum LOXL2
levels are also increased and linked to an increased risk
of disease progression (hazard ratio, 5.41; 95% CI, 1.65-chestjournal.org17.73).19,27 However, a recent therapeutic trial of an
anti-LOXL2-targeted therapy (simtuzumab) failed to
demonstrate an effect on IPF progression.133
There is some evidence that CCL18 levels can be
predictive of disease progression (eg, reduction in FVC)
and mortality in IPF.89,98 Furthermore, serum IL-6 levels
have been shown to be predictive of DLCO decline.100
Cancer antigen (CA) 19-9 and CA-125, which are
markers of epithelial damage and secreted from the
metaplastic epithelium, are also higher in patients with a
progressive disease. Rising concentrations of CA-125
over 3 months were shown to be associated with
increased risk of mortality.96 The hexameric ECM
glycoprotein tenascin C, expressed during tissue injury,651
was shown to be highly upregulated in fibrotic lungs
compared with that in normal lung tissue.97 A
correlation between lung levels of tenascin C and the
progression of lung fibrosis (percentage of FVC decline
over 6 months) has been demonstrated.97 The same
study reports tenascin C presence within fibroblastic
foci, which represent active sites of altered wound
healing in usual interstitial pneumonia.97
Genetic variants of MUC5B and TOLLIP have been
shown to have prognostic significance in IPF.92,93
Shortened telomere length has been associated with
decreased survival.94 Additionally, patients with IPF
with autoantibodies against heat shock protein 70 in
their plasma appear to have increased risk of lung
function deterioration and mortality.134
Combined assessment of multiple biomarkers appears
promising on the basis that it may enable the detection
of multiple aspects of disease progression (eg, epithelial
cell injury and repair, alveolar macrophage activation,
neutrophil recruitment or activation, or oxidative stress
in the lung).93 Investigation of the relationship between
gene expression in peripheral blood mononuclear cells
and survival among patients with IPF highlighted that
survival was lower in patients with decreased expression
of CD28, ICOS, LCK, and ITK.135 These four genes were
later confirmed, as part of a 52-gene expression
signature, to be predictive of prognosis in patients with
IPF.136 Before that, a panel of five plasma biomarkers—
MMP-7, calcium-binding protein (S100A12), IL-8,
intercellular adhesion molecule 1, and vascular cell
adhesion molecule 1—also showed potential as
predictors of IPF prognosis.87
Data in Other Chronic Fibrosing ILDs With a
Progressive Phenotype: At different cutoffs, serum KL-6
has been shown to predict lung function decline and/or
outcome in patients with CTD-ILDs, iNSIP, and
HP.56,57,101-103 In SSc-ILD, for example, serum KL-6 levels
have been associated with the degree of inflammation and
fibrosis, current impairment, and future decline in lung
function (FVC or DLCO).80,104-108 In iNSIP, patients with
higher concentrations of both KL-6 and S100A9 BALF
levels had more advanced disease with notably lower FVC,
DLCO, and 6-min walk test distance.74 High serum levels of
SP-A and/or SP-D have been associated with decreases in
DLCO and FVC in patients with diseases such as HP, iNSIP,
and SSc-ILD.13,38,57,113
In patients with SSc-ILD, serum YKL-40 elevations
appear to correlate with airway obstruction, low DLCO,
and mortality.114 Among patients with HP, increases in652 CHEST Reviewsserum YKL-40 have been correlated with DLCO and
appear to predict poor prognosis.115 In addition, there is
some evidence that serum YKL-40 may be associated
with disease activity and ongoing fibrosis in patients
with pulmonary sarcoidosis and polymyositis- and
dermatomyositis-associated ILD.116,117 High MMP-7
levels in HP have been linked with reduced survival.118
In patients with SSc-ILD, increased serum levels of
MMP-12 appear to correlate with decreased FVC, and
raised levels of tissue inhibitor of MMP-1 are associated
with decreased DLCO.119 High levels of circulating
fibrocytes have been associated with reduced lung
function and an increased risk of ILD-associated
mortality.81
Serum levels of CC16 correlate inversely with both lung
function and disease activity in patients with SSc-ILD.60
A randomized, placebo-controlled trial showed that IL-6
plays a mechanistic role in SSc-ILD, as anti-IL-6
treatment slowed the decline in FVC more than did
placebo.130 A large cohort study of patients with SSc-
ILD reported that IL-6 predicted declines in DLCO and
FVC, as well as death.100
There have been numerous reports that other
biomarkers of immune dysregulation may be
particularly associated with SSc-ILD. Elevated levels of
CRP have been linked with increased risk of
progression.108 Several studies have demonstrated
CCL18 potential as a biomarker of change in total lung
capacity, disease progression, and prognosis, although
the data on its ability to predict physiologic change are
mixed.108,126,127 BALF concentrations of CCL2 have also
been associated with lung function parameters and CT
fibrosis scores in patients with SSc-ILD.69 In line with
the data in IPF, patients with CTD-ILD or SSc-ILD
appear to have an increased risk of mortality if they also
have high levels of CA 19-9 or CA-125.118,123-125
Similarly, in CTD-ILD and HP, mortality risk has been
shown to be raised in patients with high plasma
concentrations of vascular cell adhesion molecule 1.118
Analysis of specimens from a multicenter study
suggested that the pro-angiogenic and profibrotic factor,
CXCL4, may be a useful serum biomarker for SSc-ILD
because of its correlation with pulmonary fibrosis and
disease severity.137 It may also be useful for monitoring
response to immunosuppressive therapy.138 Serum
CXCL10 may be useful in identifying progressive disease
in SSc-ILD and in predicting outcomes in pulmonary
sarcoidosis.42,139 SSc-ILD disease progression was also
correlated with high serum levels of another chemokine,[ 1 5 8 # 2 CHES T A UGU S T 2 0 2 0 ]
fractalkine (CX3CL1).140 High levels of CXCL13 have
been associated with decreased survival in patients with
CTD-ILD or HP.118
Telomere shortening also correlates with worse outcome
in chronic fibrosing ILDs with a progressive
phenotype.141 Candidate biomarkers for predicting the
development of ILD in patients with RA include anti-
citrullinated protein antibodies.142 Levels of interferon g
in the BALF of patients with RA-ILD have also been
suggested to predict the risk of disease progression.64
Patients with iNSIP with anti-MX1 autoantibodies have
been reported to have improved prognosis compared
with those without anti-MX1 autoantibodies.78 In SSc,
patients testing positive for anti-topoisomerase I (anti-
Scl-70) antibodies and negative for anticentromere
antibodies appear to have higher risk of progressive
ILD.108 Conversely, the presence of autoantibodies
against heat shock protein 70 in patients with ILDs other
than IPF does not seem to have any clinical
significance.134
There may be potential for using biomarkers to predict
acute exacerbations of fibrosing lung disease with a
progressive phenotype. Blood or serum levels of KL-6 or
a-defensins appear promising in this regard, while levels
of SP-D and leptin have also been reported to increase in
patients with acute exacerbations.10,143 However,
relatively little research has been performed in this area,
and further data are required.
Therapeutic Biomarkers
Data in IPF: KL-6 is a well-established biomarker in IPF
(Table 4).8,46,92,144-146 However, its usefulness as a
potential therapeutic biomarker is complicated by
conflicting data regarding the extent to which KL-6
levels are affected by antifibrotic (nintedanib or
pirfenidone) treatment.144TABLE 4 ] Therapeutic Biomarkers













5mC ¼ 5-methylcytosine; C1M ¼ collagen 1 degraded by MMP-2/9/13;
C3M ¼ collagen 3 degraded by MMP-9; CRPM-1/8 ¼ CRP degraded
by MMP-1/8;. See Table 1 and 2 legends for expansion of other
abbreviations.
chestjournal.orgSerum concentrations of IGFBP-2 in patients with IPF
were reported to be higher than those in healthy
subjects.46 The same study showed that IGFBP-2 levels
in patients receiving antifibrotic therapy were
significantly lower than those in untreated patients,
while remaining significantly higher than those in
healthy subjects.46 The same team later reported that
levels of the cell-free nucleosomes 5-methylcytosine and
mH2A1.1 (epigenetic biomarkers) were significantly
lowered (P < .05 and P < .01, respectively) in serum
samples from untreated patients with IPF compared
with those in patients treated with antifibrotic therapy
(pirfenidone or nintedanib).146
The rs3750920 polymorphism of TOLLIP seems to
influence the response of patients with IPF to
N-acetylcysteine therapy. Evidence for potential
interaction between N-acetylcysteine and rs35705950
within MUC5B was also observed but not significant.92
In the INMARK trial (NCT02788474) in patients with
IPF, treatment with nintedanib vs placebo for 12 weeks
did not affect the rate of change in C-reactive protein
degraded by MMP-1 and MMP-8, suggesting that it is
not a marker of response to nintedanib in patients with
IPF.8New Directions for Biomarker Development in
Chronic Fibrosing ILDs With a Progressive
Phenotype
Although numerous associations have been reported
between fibrosing ILDs and serum, BALF, and genetic
biomarkers, very few are purposefully or routinely used
in patient clinical evaluation. Most of these potential
biomarkers were investigated in an observational and
retrospective manner and, more importantly, without
robust validation of assays or replication of findings in
separate prospective cohorts. Lack of progress towards
using biomarkers in clinical practice is frustrating given
that substantial numbers of studies have been published,
for example, on MMP-7 and KL-6. Strategies for moving
the field forward in fibrosing lung disease are outlined in
Table 5. Potential biomarkers need to be thoroughly
validated according to standardized guidelines. Only
then will biomarkers gain regulatory approval and
insurance coverage, enabling their transition from
reported associations to clinical implementation.
Biomarkers have the potential to help enable differential
diagnosis (eg, between IPF and non-IPF fibrosing ILDs),
more effective patient stratification (eg, determine the
subtype of ILD or identify patients at risk of653
progression), and better up-front selection of therapy.
Most importantly, they may allow physicians to monitor
early treatment response, which remains a huge unmet
need.
Ongoing placebo-controlled clinical trials in patients
with non-IPF fibrosing ILDs involve measurement of
potential biomarkers as clinical end points. Chronic
fibrosing ILDs with a progressive phenotype are an
important emerging target for antifibrotic therapies,
with two recently published clinical trials6,7 for patients
without IPF supporting the use of antifibrotic therapy in
this patient group100 and the Food and Drug
Administration granting nintedanib breakthrough
therapy designation in this setting.
In addition to assessing biomarkers in clinical studies,
we emphasize the need to continue observing
biomarkers in large cohorts of patients, such as the
European Scleroderma Trials and Research (EUSTAR)TABLE 5 ] Proposed Approaches to Biomarker Developmen
Research Method
Validation of potential biomarkers according to FDA (United
States), EMA (Europe), and PMDA (Japan) guidelines
Clinical trial validation of putative therapeutic biomarkers
Assessment of biomarkers in large registries and
prospective cohort studies
Investigation of combinations of biomarkers
Omics analysis of multiple biomarkers and clinical data,
including pulmonary function tests, radiologic data, and
disease behavior
Unbiased biomarker discovery
EMA ¼ European Medicines Agency; FDA ¼ Food and Drug Administration; PM
654 CHEST Reviewsgroup.147 We also believe that it is important to continue
assessing biomarkers in large registries of patients, such
as the EUSTAR group or in prospective cohort studies
such as the Prospective Observation of Fibrosis in the
Lung Clinical Endpoints (PROFILE) study and those in
the IPF-Prospective Outcomes (IPF-PRO) registry.148,149
In light of the emerging new concept of chronic
fibrosing ILD with a progressive phenotype,6 effective
treatment development will require the implementation
of new specific and sensitive therapeutic biomarkers. In
terms of future research directions, we believe there is
the potential for combinations of blood biomarkers, or
even combinations of blood biomarkers with
demographic, clinical, or imaging findings, to optimize
diagnosis and disease management. Thought will need
to be given to avoid complexity and to ensure that
combinatorial biomarker signatures retain applicability
in a routine clinical setting. Multiplex biomarker assays
are in development150; such platforms should contributet
Rationale
Validation includes confirmation of biomarker behavior in
multiple prospective cohorts. The handling characteristics
of specific assays need to be defined and shown to
conform to regulatory expectations to ensure clinic
readiness.
Therapeutic biomarkers need to be tested in appropriately
designed randomized controlled trials. The relevance of
change in biomarker levels needs to be assessed against
current end points (FVC, mortality) and in exploratory
responder analyses.
Results of these studies will complement those from clinical
trials and provide further support for the clinical relevance
of the biomarker. Such studies may also be beneficial in
determining interactions based on genotype and in
identifying specific disease endotypes.
Machine learning and artificial intelligence approaches
afford the opportunity for identifying combinatorial
biomarker signatures that may be more informative than
single markers alone. Such strategies have the potential
to integrate information from multiple pathogenic
pathways (eg, epithelial turnover, matrix synthesis and
degradation, and inflammatory cell activation). A danger
of this approach is increased complexity; ultimately, any
multibiomarker signature needs to retain clinical
relevance to ensure use in practice.
In relation to a progressive phenotype, omics analysis may
help identify the best biomarkers or combinations of
biomarkers for diagnosis, treatment, and prognosis.
The advent of novel, unbiased broad-scale proteomic assays
affords the opportunity for identifying novel disease
biomarkers. Any proteins identified in this way will need
robust validation as outlined in the earlier steps.
DA ¼ Pharmaceuticals and Medical Devices Agency.
[ 1 5 8 # 2 CHES T A UGU S T 2 0 2 0 ]
to enhanced screening, prognostication, and care.
Analysis of biomarkers relating to a particular therapy
could be useful for predicting the likelihood of a
response to the treatment.151 Finally, emergence of novel
categories of biomarkers (eg, exosomes, mitochondrial
DNA, microRNA, quantitative imaging, transcriptomics,
microbiome related) offer new and thriving areas of
research that should complement and strengthen
existing biomarker strategies.152Conclusions
In the challenging field of chronic fibrosing ILDs with a
progressive phenotype, successful biomarker
development should improve the diagnosis and
prediction of longitudinal disease behavior (eg, identify
the subgroups of patients most at high risk of disease
progression), as well as monitoring and enabling
measurement of the outcomes of treatment. In the
future, it is hoped that the ongoing implementation of
multiple biomarker analyses in large international,
prospective, and adequately powered clinical studies will
deliver clinically significant data that will convince
physicians of the value of using biomarkers at multiple
stages of the diagnosis and management of chronic
fibrosing ILDs with a progressive phenotype.
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124. Sargin G, Köse R, Şentürk T. Tumor-associated antigens in
rheumatoid arthritis interstitial lung disease or malignancy? Arch
Rheumatol. 2018;33(4):431-437.
125. Xu F, Cui W, Wei Y, Dong J, Liu B. Association of serum tumor
markers with interstitial lung disease in patients with or without
connective tissue disease: a cross-sectional study. Tradit Med Mod
Med. 2018;1(2):145-151.
126. Hoffmann-Vold AM, Tennøe AH, Garen T, et al. High level of
chemokine CCL18 is associated with pulmonary function
deterioration, lung fibrosis progression, and reduced survival in
systemic sclerosis. Chest. 2016;150(2):299-306.
127. Schupp J, Becker M, Günther J, Müller-Quernheim J,
Riemekasten G, Prasse A. Serum CCL18 is predictive for lung
disease progression and mortality in systemic sclerosis. Eur Respir J.
2014;43(5):1530-1532.
128. Cai M, Bonella F, He X, et al. CCL18 in serum, BAL fluid and
alveolar macrophage culture supernatant in interstitial lung
diseases. Respir Med. 2013;107(9):1444-1452.
129. Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of
candidate serum biomarkers for systemic sclerosis-associated
interstitial lung disease. Arthritis Rheumatol. 2019;71(6):972-982.
130. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of
subcutaneous tocilizumab in adults with systemic sclerosis
(faSScinate): a phase 2, randomised, controlled trial. Lancet.
2016;387(10038):2630-2640.
131. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical
interstitial lung disease in rheumatoid arthritis. Arch Intern Med.
2008;168(2):159-166.
132. Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in
collagen degradation biomarkers in idiopathic pulmonary fibrosis:
an analysis from the prospective, multicentre PROFILE study.
Lancet Respir Med. 2015;3(6):462-472.
133. Gilead Sciences, Inc. Gilead terminates phase 2 study of
simtuzumab in patients with idiopathic pulmonary fibrosis. http://
www.gilead.com/news/press-releases/2016/1/gilead-terminates-
phase-2-study-of-simtuzumab-in-patients-with-idiopathic-
pulmonary-fibrosis. Accessed May 16, 2018.
134. Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic
pulmonary fibrosis with antibodies to heat shock protein 70 have
poor prognoses. Am J Respir Crit Care Med. 2013;187(7):768-775.
135. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood
mononuclear cell gene expression profiles predict poor outcome in[ 1 5 8 # 2 CHES T A UGU S T 2 0 2 0 ]
idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5(205).
205ra136.
136. Herazo-Maya JD, Sun J, Molyneaux PL, et al. Validation of a 52-
gene risk profile for outcome prediction in patients with idiopathic
pulmonary fibrosis: an international, multicentre, cohort study.
Lancet Respir Med. 2017;5(11):857-868.
137. van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and
CXCL4 as a biomarker in systemic sclerosis. N Engl J Med.
2014;370(5):433-443.
138. Volkmann ER, Tashkin DP, Roth MD, et al. Changes in plasma
CXCL4 levels are associated with improvements in lung function in
patients receiving immunosuppressive therapy for systemic
sclerosis-related interstitial lung disease. Arthritis Res Ther.
2016;18(1):305.
139. Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible
chemokines reflect severity and progression in sarcoidosis. Respir
Res. 2013;14(1):121.
140. Hoffmann-Vold AM, Weigt SS, Palchevskiy V, et al. Augmented
concentrations of CX3CL1 are associated with interstitial lung
disease in systemic sclerosis. PLoS One. 2018;13(11):e0206545.
141. Newton CA, Oldham JM, Ley B, et al. Telomere length and genetic
variant associations with interstitial lung disease progression and
survival. Eur Respir J. 2019;53(4):1801641.
142. Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid
arthritis-interstitial lung disease is enhanced by serum biomarkers.
Am J Respir Crit Care Med. 2015;191(12):1403-1412.
143. Leuschner G, Behr J. Acute exacerbation in interstitial lung disease.
Front Med (Lausanne). 2017;4:176.chestjournal.org144. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T.
Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis
in clinical practice. Respir Med. 2013;107(9):1431-1437.
145. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-
controlled trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040-
1047.
146. Guiot J, Struman I, Chavez V, et al. Altered epigenetic features in
circulating nucleosomes in idiopathic pulmonary fibrosis. Clin
Epigenetics. 2017;9:84.
147. Tyndall A, Ladner UM, Matucci-Cerinic M. The EULAR
Scleroderma Trials and Research Group (EUSTAR): an
international framework for accelerating scleroderma research.
Curr Opin Rheumatol. 2008;20(6):703-706.
148. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking
biomarker discovery. Eur Respir Rev. 2013;22(128):148-152.
149. Todd JL, Neely ML, Overton R, et al. Peripheral blood proteomic
profiling of idiopathic pulmonary fibrosis biomarkers in the
multicentre IPF-PRO Registry. Respir Res. 2019;20(1):227.
150. Summit rAI. Paper presented at: 3rd Annual IPF Summit; August
27-29, 2019; San Diego, CA.
151. Hoffmann-Vold AM, Weigt SS, Saggar R, et al. Endotype-
phenotyping may predict a treatment response in progressive
fibrosing interstitial lung disease. EBioMedicine. 2019;50:379-386.
152. Ryu C, Sun H, Gulati M, et al. Extracellular mitochondrial DNA is
generated by fibroblasts and predicts death in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 2017;196(12):1571-1581.659
